All In Biotech

BLA 103836 · Horizon Therapeutics Ireland Dac

Actimmune

Interferon Gamma-1b · Single-Use · Interferon gamma

NovelOrphan

Last checked: Nov 20, 2026Latest source record: Aug 27, 2015 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

1999

Feb 25, 1999

Approved uses

n/a

Original approval plus efficacy supplements

Registered trials

157

30 Phase 3, 19 recruiting

FAERS reports

0

0 serious, 0 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

What it is approved for

No structured label for this application in openFDA. Older and discontinued products often have none.

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

FDA's data service is rate-limiting requests. Try again in a minute. The numbers below may be missing or incomplete.

No approvals could be loaded from Drugs@FDA just now.

Clinical trials

Interventional ClinicalTrials.gov studies with "Interferon Gamma-1b" as an intervention, any sponsor and status, largest first.

All 157 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
FDA's data service is rate-limiting requests. Try again in a minute. The numbers below may be missing or incomplete.

No FAERS reports name this application.

FAERS reports by year

By the date FDA received the report.

No reports.

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Part D: Actimmune (Interferon Gamma-1b,Recomb.)

2024 spending

$27.6M

Beneficiaries

47

433 claims

Per beneficiary

$588,093

$10,983.66 per unit

View as table
YearSpending
2020$23,353,185
2021$25,309,639
2022$27,310,873
2023$26,300,697
2024$27,640,388

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 36 on PubMed

Sponsor: Amgen

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.